Telangiectasia Clinical Trial
Official title:
A Single-Center Prospective, Open-Label Study of the Excel V 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte
NCT number | NCT01491620 |
Other study ID # | C-11-XPC01 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 2011 |
Est. completion date | May 2013 |
Verified date | October 2022 |
Source | Cutera Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the safety and efficacy of the Excel V 532 nm KTP laser for the treatment of dyschromia of the neck and/or chest (poikiloderma of Civatte).
Status | Completed |
Enrollment | 24 |
Est. completion date | May 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Years to 65 Years |
Eligibility | Inclusion Criteria: - Fitzpatrick Skin Type I - III - Clinical diagnosis of poikiloderma of Civatte affecting the neck and/or chest - Willing to refrain from using topical corticosteroids, retinoids and bleaching agents on the treated area - Agree not to undergo any other procedure for the treatment of poikiloderma of Civatte during the study - Willing and able to read, understand and sign the Informed Consent Form - Willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions Exclusion Criteria: - Any laser treatment on neck and/or chest within 12 months - Any topical treatment on neck and/or chest within 6 months - Pregnant and/or breastfeeding - Infection, dermatitis or a rash in the treatment area - Suffering from significant concurrent illness, such as Diabetes Mellitus or pertinent neurological disorders - History of seizure disorders due to light, fibromyalgia, connective tissue disease, vitiligo, psoriasis, pigmentary disorders, keloid scarring, hypertrophic scarring or abnormal wound healing - History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications - Having a known anticoagulative condition or taking anticoagulation medications - History of diseases stimulated by heat, unless treatment is conducted following a prophylactic regimen - Having undergone any surgery in the treatment area within 6 months of treatment (or more if skin has not healed completely) - History of radiation to the head, neck and/or upper chest - Undergoing systemic chemotherapy for the treatment of cancer - Systemic use of isotretinoin (Accutane®) within 6 months - Any use of gold therapy - Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study - Current smoker or history of smoking within 12 months of study - Participation in a study of another device or drug within 6 months - As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in study |
Country | Name | City | State |
---|---|---|---|
United States | Zel Skin and Laser Specialists | Edina | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Cutera Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Severity Assessment Score | Change in Physician's Severity Assessment score based on blinded assessment of subject photographs by a panel of independent dermatologists.
Blinded Physician's Severity Assessment (min=1;max=4); Higher scores mean worse values |
24 weeks | |
Primary | Physician's Global Assessment (Blinded) | Before and after subject photographs were presented to a panel of independent dermatologists. The panel was blinded to treatment parameters and the photograph time points. Each dermatologist was asked to select the baseline photograph and then rate improvement in Poikiloderma of Civatte in the post-treatment photograph using a 5-point improvement scale.
Physician's Global Assessment (min= -1; max=4) Higher scores mean better outcome |
24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Completed |
NCT00378196 -
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
|
Phase 1 | |
Terminated |
NCT04336163 -
Skin Imaging to Inform Laser Treatments
|
N/A | |
Completed |
NCT02286804 -
Ultherapy for the Treatment of Spider Veins on the Legs
|
N/A | |
Completed |
NCT03472859 -
Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser
|
N/A | |
Recruiting |
NCT06259292 -
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
|
||
Completed |
NCT04148950 -
Effects of Kinesio Taping Method on Functional Capacity and Quality of Life in Patients With Chronic Venous Disease
|
N/A | |
Completed |
NCT00457067 -
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation
|
Phase 1 | |
Completed |
NCT00457145 -
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
|
Phase 1 | |
Completed |
NCT04795310 -
Clinical Observation of Pulsed Dye Laser and Intense Pulsed Light in Treating Facial Telangiectasia
|
N/A | |
Completed |
NCT04274842 -
D-OCT of Facial Telangiectasia Treated With IPL
|
N/A | |
Recruiting |
NCT05978986 -
Efficiency of Determining the Clinical Class of Chronic Venous Disorders by Artificial Intelligence
|
N/A | |
Completed |
NCT05036200 -
Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma
|
N/A |